Selected article for: "Arbidol group and control group"

Author: Yueping Li; Zhiwei Xie; Weiyin Lin; Weiping Cai; Chunyan Wen; Yujuan Guan; Xiaoneng Mo; Jian Wang; Yaping Wang; Ping Peng; Xudan Chen; Wenxin Hong; Guangming Xiao; Jinxin Liu; Lieguang Zhang; Fengyu Hu; Feng Li; Feng Li; Fuchun Zhang; Xilong Deng; Linghua Li
Title: An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)
  • Document date: 2020_3_23
  • ID: 9hknw4ws_57
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.19.20038984 doi: medRxiv preprint author/funder, who has granted medRxiv a license to display the preprint in perpetuity. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. hypertension and 2 with both in the LPV/r group; one patient with Coronary Heart Disease, 3 hypertension and 1 chronic liver disea.....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.19.20038984 doi: medRxiv preprint author/funder, who has granted medRxiv a license to display the preprint in perpetuity. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. hypertension and 2 with both in the LPV/r group; one patient with Coronary Heart Disease, 3 hypertension and 1 chronic liver disease in the arbidol group; and one patient with Coronary Heart Disease, 2 hypertension, 2 chronic liver disease and 1 with both diabetes and chronic liver disease in the control group.

    Search related documents:
    Co phrase search for related documents